On Thursday, ESSA Pharma Inc. ( EPIX ) announced its plans to terminate the Phase 2 trial of masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer (mCRPC) naïve to second-generation antiandrogens. This decision was based on a protocol-specified interim review of the safety, PK, and efficacy data, which showed a much higher rate...

09:27 AM EDT, 11/01/2024 (MT Newswires) -- Thumzup Media ( TZUP ) said Friday that underwriter Dawson James Securities fully exercised its overallotment option, increasing the gross proceeds from Thumzup's public offering to about $8.2 million. The company said Dawson James Securities purchased an additional 213,750 shares at $5 each, raising the total number of shares sold to about 1.6...

09:27 AM EDT, 11/01/2024 (MT Newswires) -- Exxon Mobil ( XOM ) on Friday reported better-than-expected third-quarter results as higher oil production helped offset lower industry refining margins and prices. The oil giant's adjusted earnings came in at $1.92 per share for the September quarter, compared with the Capital IQ-polled consensus of $1.89. Total revenue and other income declined to...

LyondellBasell Industries N.V. ( LYB ) shares are trading lower after the company reported worse-than-expected third-quarter results. LYB reported revenues of $10.332 billion, down 2.8% year over year and missing the consensus of $10.601 billion. Adjusted EBITDA stood at $1.21 billion (-14.1% Y/Y), and the margin contracted by 154 bps to 11.7%. Adjusted EPS stood at $1.88, below the consensus...